2019
The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery
Mansour SG, Zhang WR, Moledina D, Coca SG, Jia Y, Thiessen-Philbrook H, McArthur E, Inoue K, Koyner JL, Shlipak MG, Wilson FP, Garg AX, Ishibe S, Parikh CR, Consortium T. The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery. American Journal Of Kidney Diseases 2019, 74: 36-46. PMID: 30955944, PMCID: PMC6591032, DOI: 10.1053/j.ajkd.2019.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersCardiac Surgical ProceduresCreatinineEndpoint DeterminationFemaleHumansKidneyMaleMiddle AgedNeovascularization, PhysiologicOutcome Assessment, Health CarePostoperative ComplicationsProspective StudiesReceptors, Vascular Endothelial Growth FactorRisk AssessmentUnited StatesVascular Endothelial Growth Factor AConceptsAcute kidney injuryCardiac surgeryAKI durationKidney injuryProangiogenic markersAngiogenesis markersOutcomes of AKILong-term outcomesPlasma VEGF concentrationsTRIBE-AKI cohortAntiangiogenic markersCause mortalityPreoperative concentrationsHospital dischargeProcess of angiogenesisMarker levelsVEGFR1 levelsPGF concentrationsHigher oddsMortality riskHigh riskLower oddsVEGF concentrationsAngiogenic markersSurgery
2017
Evaluating biomarkers for prognostic enrichment of clinical trials
Kerr KF, Roth J, Zhu K, Thiessen-Philbrook H, Meisner A, Wilson FP, Coca S, Parikh CR. Evaluating biomarkers for prognostic enrichment of clinical trials. Clinical Trials 2017, 14: 629-638. PMID: 28795578, PMCID: PMC5714681, DOI: 10.1177/1740774517723588.Peer-Reviewed Original ResearchConceptsPrognostic enrichmentTrial eligibility criteriaClinical trialsEligibility criteriaTrial resultsClinical trial sample sizesOutcomes of interestTrial sample sizeTrial metricsOnly patientsBACKGROUND/Prognostic biomarkerPrognostic performanceHigh riskClinical settingScreening costsBiomarkersTrialsScreening thresholdCalendar timeTrial costsSample sizePatients